Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019

被引：8
|
作者：
Kherabi, Yousra [1 ]
Frechet-Jachym, Mathilde [3 ]
Rioux, Christophe [1 ,4 ]
Yazdanpanah, Yazdan [1 ,2 ,4 ,5 ,6 ]
Mechai, Frederic [7 ,8 ]
Pourcher, Valerie [9 ]
Robert, Jerome [2 ,10 ]
Guglielmetti, Lorenzo [2 ,10 ]
机构：
[1] Hop Bichat Claude Bernard, Assistance Publ Hop Paris, Paris, France
[2] Sorbonne Univ, INSERM, U1135, Paris, France
[3] Ctr Hosp Bligny, Briis Sous Forges, France
[4] Assistance Publ Hop Paris, Paris, France
[5] Univ Paris, INSERM, IAME, Paris, France
[6] Univ Paris Diderot, Paris, France
[7] Hop Avicenne, Assistance Publ Hop Paris, Paris, France
[8] Hop Avicenne, Bobigny, France
[9] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Paris, France
[10] Sorbonne Univ, Hop Pitie Salpetriere, Assistance Publ Hop Paris, Paris, France
来源：
EMERGING INFECTIOUS DISEASES | 2022年 / 28卷 / 09期
关键词：
CULTURE CONVERSION; XDR-TB; FLUOROQUINOLONES; TOLERABILITY; SAFETY; IMPACT;
D O I：
10.3201/eid2809.220458
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006-2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were preXDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
引用
收藏
页码：1796 / 1804
页数：9
相关论文
共 50 条
  • [31] Pulmonary tuberculosis in young Korean soldiers: incidence, drug resistance and treatment outcomes
    Kang, C-I.
    Choi, C-M.
    Kim, D-H.
    Kim, C-H.
    Lee, D-J.
    Kim, H-B.
    Kim, N-J.
    Oh, M-D.
    Choe, K. W.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2006, 10 (09) : 970 - 974
  • [32] Pattern of primary tuberculosis drug resistance and associated treatment outcomes in Transnistria, Moldova
    Dolgusev, O.
    Obevzenco, N.
    Padalco, O.
    Pankrushev, S.
    Ramsay, A.
    Van den Bergh, R.
    Manzi, M.
    Denisiuk, O.
    Zachariah, R.
    PUBLIC HEALTH ACTION, 2014, 4 : S64 - S66
  • [33] Outcomes Research - DOTS Treatment in Extrapulmonary Tuberculosis of Different Organ Systems Under Revised National Tuberculosis Control Program - South Kerala
    Cherian, Jerin J.
    Kiruthika, K. P.
    Subramoniapillai, Jaysankar
    Pillai, Pradeep S.
    INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 : S59 - S59
  • [34] Pyrazinamide Resistance, Mycobacterium tuberculosis Lineage and Treatment Outcomes in San Francisco, California
    Budzik, Jonathan M.
    Jarlsberg, Leah G.
    Higashi, Julie
    Grinsdale, Jennifer
    Hopewell, Phil C.
    Kato-Maeda, Midori
    Nahid, Payam
    PLOS ONE, 2014, 9 (04):
  • [35] Impact of mono- and poli-resistance on the treatment outcomes of pulmonary tuberculosis
    Evelina, Lesnic
    Niguleanu, Adriana
    Ustian, Aurelia
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [36] Treatment of Tuberculosis in a Region with High Drug Resistance: Outcomes, Drug Resistance Amplification and Re-Infection
    Bonnet, Maryline
    Pardini, Manuela
    Meacci, Francesca
    Orru, Germano
    Yesilkaya, Hasan
    Jarosz, Thierry
    Andrew, Peter W.
    Barer, Mike
    Checchi, Francesco
    Rinder, Heinz
    Orefici, Graziella
    Ruesch-Gerdes, Sabine
    Fattorini, Lanfranco
    Oggioni, Marco Rinaldo
    Melzer, Juliet
    Niemann, Stefan
    Varaine, Francis
    PLOS ONE, 2011, 6 (08):
  • [37] A model-based investigation into urban-rural disparities in tuberculosis treatment outcomes under the Revised National Tuberculosis Control Programme in India
    Singh, Himanshu
    Ramamohan, Varun
    PLOS ONE, 2020, 15 (02):
  • [38] Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru
    Magee, M. J.
    Bloss, E.
    Shin, S. S.
    Contreras, C.
    Arbanil Huaman, H.
    Calderon Ticona, J.
    Bayona, J.
    Bonilla, C.
    Yagui, M.
    Jave, O.
    Cegielski, J. P.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (06) : E404 - E412
  • [39] Initial drug resistance and tuberculosis treatment outcomes: Systematic review and meta-analysis
    Lew, Woojin
    Pai, Madhukar
    Oxlade, Olivia
    Martin, Daniel
    Menzies, Dick
    ANNALS OF INTERNAL MEDICINE, 2008, 149 (02) : 123 - 134
  • [40] The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity
    Click, E. S.
    Chirenda, J.
    Kibias, S.
    Menzies, H. J.
    Oeltmann, J. E.
    Sentle, C.
    Muribe, T.
    Lere, T. D.
    Makombe, R.
    Bamrah, S.
    Moore, B. K.
    Cain, K. P.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (11) : 1319 - 1322
12345